Regulatory Blog

Improving the availability of medicines authorised in the European Union is a key priority for the European Medicines Regulatory Network. Supply chain disruptions can affect the continuity of medicine supply, making it important for Marketing Authorisation Holders (MAHs) to identify potential risks and establish measures to reduce the likelihood of shortages. The European Medicines Agency (EMA) has published guidance and a template for industry on implementing Shortage Preven

Ensuring the availability and continuity of medicines across the European Union is an important priority for the European Medicines Regulatory Network. Supply chain disruptions can affect medicine availability, making it important for Marketing Authorisation Holders (MAHs) to identify potential risks and establish appropriate measures to reduce the likelihood of shortages. The European Medicines Agency (EMA) has published the Guidance for industry on implementing Shortage Pre